Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017443 | 0.92 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL4010285 | 0.92 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL4012376 | 0.90 | NR1H2 (0.88) | NR1H2NR1H3 | |
| SCHEMBL4018750 | 0.90 | NR1H2 (0.88) | NR1H2NR1H3 | |
| SCHEMBL4010850 | 0.87 | NR1H2 (0.83) | NR1H2NR1H3 | |
| SCHEMBL4015435 | 0.87 | NR1H3 (1.00) | NR1H2NR1H3 | |
| SCHEMBL4013504 | 0.85 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL4012166 | 0.85 | NR1H2 (0.80) | NR1H2NR1H3 | |
| SCHEMBL4017334 | 0.84 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL4013271 | 0.84 | NR1H2 (0.82) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | claimed |
| US-9962348-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962348-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170319525-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319525-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319525-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | NR1H2 4537/4885NR1H3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.